The need for better focus on primary and secondary prevention of cardiovascular disease

This report summarises the limited improvement in the use of highly cost-effective pharmaceutical treatment for primary and secondary prevention of cardiovascular disease (CVD) over the past few years in New Zealand. It provides a number of new analyses to give further insights to the persistently wide unexplained treatment gaps in the management of CVD and a number of recommendations to optimise population health gain and equity in a sustainable manner.